Keyphrases
AIDS Clinical Trials
13%
AIDS/HIV
100%
Ampicillin
13%
Ampicillin Resistance
11%
Antibiotics
16%
Antiretroviral
11%
Antiretroviral Therapy
27%
Bacteremia
16%
Ceftriaxone
27%
Cerebrospinal Fluid
15%
Combined Antiretroviral Therapy (cART)
14%
Disease Severity
11%
Haemophilus Influenzae
24%
Haemophilus Influenzae Type b
29%
Highly Active Antiretroviral Therapy (HAART)
24%
HIV Patients
20%
HIV-infected children
41%
Human Immunodeficiency Virus Infection
23%
Human Immunodeficiency Virus Type 1 (HIV-1)
44%
Immunogenicity
16%
Infected children
52%
Infections in children
26%
Invasive Pneumococcal Disease
12%
Lamivudine
11%
Lopinavir
13%
Meningitis
29%
Nevirapine
15%
Non-susceptible
12%
Older Adults
12%
Pediatric
23%
Pediatric AIDS
12%
Pediatric Patients
26%
Penicillin
25%
Perinatally Acquired HIV
11%
Perinatally HIV-infected
12%
Pharmacokinetics
63%
Placebo
16%
Preadolescent children
10%
Protease Inhibitors
20%
Respiratory Syncytial Virus
19%
Rifampin
11%
Ritonavir
30%
S. Pneumoniae
10%
Stavudine
12%
Streptococcus Pneumoniae
15%
United States
24%
Vaccination
12%
Viral Load
12%
Young children
11%
Zidovudine
18%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
9%
Amikacin
10%
Aminoglycoside
6%
Ampicillin
9%
Antibiotics
11%
Antiinfective Agent
6%
Bacterial Infection
7%
Bacterial Meningitis
8%
Bloodstream Infection
13%
Ceftriaxone
23%
Chickenpox Vaccine
6%
Chloramphenicol
9%
Clindamycin
7%
Clinical Trial
15%
Combination Therapy
9%
Cotrimoxazole
6%
Darunavir Plus Ritonavir
6%
Didanosine
9%
Diseases
25%
Haemophilus influenzae
8%
Haemophilus Influenzae Type B
12%
Haemophilus Meningitis
6%
HIV
98%
Human Immunodeficiency Virus 1
15%
Human Immunodeficiency Virus Infection
21%
Human Respiratory Syncytial Virus
6%
Immunogenicity
10%
Infection
50%
Lamivudine
7%
Linezolid
8%
Live Attenuated Influenza Vaccine
6%
Lopinavir Plus Ritonavir
10%
Measles Mumps Rubella Vaccine
6%
Meningitis
24%
Nevirapine
12%
Penicillin
25%
Pharmacokinetics
81%
Placebo
10%
Pneumococcal Infection
14%
Pneumococcus Vaccine
7%
Proteinase Inhibitor
14%
Rifampicin
12%
Ritonavir
20%
Sepsis
7%
Shunt Infection
6%
Stavudine
15%
Streptococcus Group A
6%
Streptococcus Pneumonia
11%
Tolerability
8%
Zidovudine
13%
Medicine and Dentistry
Antibiotics
5%
Antiretroviral Therapy
17%
Bacterial Meningitis
6%
Bloodstream Infection
6%
Brain Ventricle Peritoneum Shunt
5%
Cerebrospinal Fluid Shunting
5%
Clinical Trial
10%
Combination Therapy
6%
Cytotoxic T-Cell
5%
Diseases
29%
Gestational Age
5%
Haemophilus Influenzae Type B
5%
HIV/AIDS
5%
Human Immunodeficiency Virus
50%
Human Immunodeficiency Virus 1
6%
Human Immunodeficiency Virus Infection
12%
Infection
25%
Meningitis
5%
Neonatal Infant
8%
Pathogen
7%
Pediatrics
31%
Pediatrics Patient
6%
Penicillin
9%
Pneumococcal Infection
10%
Pneumococcal Pneumonia
7%
Pneumococcus
5%
Pneumococcus Vaccine
5%
Proteinase Inhibitor
5%
Ritonavir
6%
Sepsis
6%
Serotype
8%
Shunt Infection
8%
Streptococcus Pneumonia
7%